Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib

Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib

Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy, largely due to metastasis and drug resistant recurrences. Fifteen percent of ovarian tumors carry mutations in BRCA1 or BRCA2, rendering them vulnerable to treatment with PARP inhibitors such as olaparib. Recent studies...

Full description

Bibliographic Details
Main Authors: Cai M. Roberts, Mehida Rojas-Alexandre, Ruth E. Hanna, Z. Ping Lin, Elena S. Ratner
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Cancers
Subjects:
ovarian cancer
PARP inhibitors
epithelial to mesenchymal transition
drug response
Online Access:https://www.mdpi.com/2072-6694/15/15/3919

Internet

https://www.mdpi.com/2072-6694/15/15/3919

Similar Items